THERAPEUTIC AREA

Cardiovascular
 

Cardiovascular

Cardiovascular
Cardiovascular disease
including
heart disease
and stroke

is a major
global health concern and the leading cause of death and disability worldwide1

 
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).
 

1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.



Learn more

Metabolic

Metabolic
2.3

million people

About 2.3 million people in South Africa were living with type 2 diabetes in 2015 accounting for 7% of the population.>

About 2.3 million people in South Africa were living with type 2 diabetes in 2015 accounting for 7% of the population. This number is projected to increase to 4 million by 2035, a 55% increase in prevalence, the biggest driver being obesity. Type 2 diabetes is a chronic, progressive condition and long term complications include strokes, heart attack, and cardiovascular death, as well as diabetic kidney disease, retinopathy, arm and leg amputation, and autonomic neuropathy. In addition to the now marketed products from our own R & D we are also focussed cardio-metabolic indications with a high unmet medical need. Learn more
 
Metabolic

EXPLORE OUR CONTENT

Mechanism of Action

icoPDF

10/09/2019
Author: Boehringer Ingelheim

Mechanism of Action

Mechanism of Action

NOAC safety in clinical practice: Evidence from the real world 06:52
10/09/2019
Author: Boehringer Ingelheim

NOAC safety in clinical practice: Evidence from the real world

NOAC safety in clinical practice: Evidence from the real world